Compare KORE & ASRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KORE | ASRT |
|---|---|---|
| Founded | 2003 | 1995 |
| Country | United States | United States |
| Employees | 539 | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 89.6M | 76.0M |
| IPO Year | N/A | 2004 |
| Metric | KORE | ASRT |
|---|---|---|
| Price | $8.96 | $11.61 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $5.00 | ★ $35.00 |
| AVG Volume (30 Days) | ★ 143.7K | 29.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 95.07 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $124,961,000.00 |
| Revenue This Year | $1.26 | N/A |
| Revenue Next Year | $7.55 | $1.42 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.00 | $0.51 |
| 52 Week High | $9.00 | $12.95 |
| Indicator | KORE | ASRT |
|---|---|---|
| Relative Strength Index (RSI) | 89.43 | 53.65 |
| Support Level | $4.67 | $11.05 |
| Resistance Level | N/A | $12.75 |
| Average True Range (ATR) | 0.11 | 0.45 |
| MACD | 0.29 | -0.17 |
| Stochastic Oscillator | 99.05 | 52.41 |
Kore Group Holdings Inc provides Internet of Things (IoT) solutions and services. In addition to providing critical services to customers globally, it enables them to manage, deploy, and scale their IoT applications and use cases. It offers connectivity services, location-based services, device solutions, and managed and professional services for the development and support of IoT technology for the Machine-to-Machine market. It derives revenue from IoT Connectivity services, IoT Solutions services, SIMs (IoT Connectivity), and IoT devices (IoT Solutions). Geographically, the company generates the majority of its revenue from the United States and the rest from other countries.
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain.